NCT06459791Recruiting
Efficacy of Personalized Tumorogram-based Therapy in Cancer Established From Patient-derived Organoid (AVATAR)
Efficacy of Personalized Tumorogram-based Therapy in Cancer Established From Patient-derived Biological Avatar: Proof-of-concept Study
Source: ClinicalTrials.gov · Last updated 29 Jan 2026
Brief summary (registry, in English)
A biopsy of a tumor lesion (breast or other localisation) will be performed for processing to establish avatars (patient-derived organoids -PDO). A personalized tumorogram for each patient will be provided, based on the results of the drug screening (= tumor predicted as sensitive, intermediate, resistant or non-evaluable for each drug tested). Patients with an informative tumorogram will receive one of the recommended treatments (line N+1) in the event of tumor progression, administered according to standard procedures and validated at medical meetings specific to each center, and their fate will be monitored.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 110 (estimated)
- First submitted
- 27 May 2024
- Start date
- 6 Dec 2024
- Primary completion date
- 15 Dec 2027
- Lead sponsor
- Institut Curie
- Diseases
- Metastatic breast cancer
- NCT number
- NCT06459791
What you commit to
- Study type: Interventional
- Planned participants: 110
- From 6 Dec 2024 to the primary completion date, 15 Dec 2027
- 3 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- More than 3 lines of chemotherapy in the advanced setting (excluding hormone therapy/CDK4/6 inhibitor)
Other
- Progressive brain metastases
- Leptomeningeal metastasis
Who the study is looking for
- Patient over 18 years of age
- Advanced breast cancer
- Triple-negative phenotype (HR-/HER2-) or HR+/HER2- after hormone resistance (progression after treatment with hormone therapy + CDK4/6 inhibitor)
- Tumor measurable according to RECISTv1.1 criteria, accessible to biopsy
- Performans Status 0-1
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (3)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Hôpital Saint-Louis - AP-HP Senopole Coordinator of this site? Confirm its status | Paris | France | Not yet recruiting |
| Institut Curie Coordinator of this site? Confirm its status | Paris | France | Recruiting |
| Institut Curie Coordinator of this site? Confirm its status | Saint-Cloud | France | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.